Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Vaccine ; 28(34): 5558-64, 2010 Aug 02.
Article in English | MEDLINE | ID: mdl-20600509

ABSTRACT

A recombinant humanized antibody to Venezuelan equine encephalitis virus (VEEV) was constructed in a monocistronic adenoviral expression vector with a foot-and-mouth-disease virus-derived 2A self-cleavage oligopeptide inserted between the antibody heavy and light chains. After expression in mammalian cells, the heavy and light chains of the humanized antibody (hu1A4A1IgG1-2A) were completely cleaved and properly dimerized. The purified hu1A4A1IgG1-2A retained VEEV binding affinity and neutralizing activity similar to its parental murine antibody. The half-life of hu1A4A1IgG1-2A in mice was approximately 2 days. Passive immunization of hu1A4A1IgG1-2A in mice (50 microg/mouse) 24 h before or after virulent VEEV challenge provided complete protection, indicating that hu1A4A1IgG1-2A has potent prophylactic and therapeutic effects against VEEV infection.


Subject(s)
Antibodies, Monoclonal/therapeutic use , Antibody Specificity , Encephalomyelitis, Venezuelan Equine/prevention & control , Immunization, Passive , Animals , Antibodies, Monoclonal/biosynthesis , Antibodies, Monoclonal/immunology , Cell Line , Encephalitis Virus, Venezuelan Equine/immunology , Half-Life , Humans , Mice , Mice, Inbred BALB C , Neutralization Tests , Viral Proteins/immunology
SELECTION OF CITATIONS
SEARCH DETAIL